L
Lianzhu Liang
Researcher at Merck & Co.
Publications - 17
Citations - 592
Lianzhu Liang is an academic researcher from Merck & Co.. The author has contributed to research in topics: In vivo & Aurora inhibitor. The author has an hindex of 9, co-authored 15 publications receiving 512 citations.
Papers
More filters
Journal ArticleDOI
Restoring Methicillin-Resistant Staphylococcus aureus Susceptibility to β-Lactam Antibiotics
Christopher M. Tan,Alex G. Therien,Jun Lu,Sang Ho Lee,Alexandre Caron,Charles Gill,Christian Lebeau-Jacob,Liliana L. Benton-Perdomo,João M. Monteiro,Pedro M. Pereira,Nathaniel L. Elsen,Jin Wu,Kathleen Deschamps,Mihai Petcu,Simon Wong,Etienne Daigneault,Susanne Kramer,Lianzhu Liang,Eugene Maxwell,David Claveau,John P. Vaillancourt,Kathryn Skorey,John Tam,Hao Wang,Timothy C. Meredith,Susan Sillaots,Lisa Wang-Jarantow,Yeeman K. Ramtohul,Eric Langlois,John C. Reid,Gopal Parthasarathy,Sujata Sharma,Anastasia Baryshnikova,Kevin J. Lumb,Mariana G. Pinho,Stephen M. Soisson,Terry Roemer +36 more
TL;DR: A Staphylococcus aureus antisense knockdown strategy is adapted to genetically identify the cell division Z ring components—FtsA, FtsZ, and FtsW—as β-lactam susceptibility determinants of methicillin-resistant S. aureUS to support a target-based approach to develop synergistic drug combinations to combat MRSA with improved efficacy and reduced potential for drug resistance.
Journal ArticleDOI
Discovery of Wall Teichoic Acid Inhibitors as Potential Anti-MRSA β-Lactam Combination Agents
Hao Wang,Charles Gill,Sang Ho Lee,Paul Mann,Paul Zuck,Timothy C. Meredith,Nicholas Murgolo,Xinwei She,Susan Kales,Lianzhu Liang,Jenny Liu,Jin Wu,John P. Santa Maria,Jing Su,Jianping Pan,Judy Hailey,Debra Mcguinness,Christopher M. Tan,Amy M. Flattery,Suzanne Walker,Todd A. Black,Terry Roemer +21 more
TL;DR: In this article, the potential of wall teichoic acid (WTA) biosynthesis inhibitors as combination agents to restore β-lactam efficacy against MRSA was investigated.
Journal ArticleDOI
TarO-specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci
Sang Ho Lee,Hao Wang,Marc A. Labroli,Sandra Koseoglu,Paul Zuck,Todd Mayhood,Charles Gill,Paul Mann,Xinwei Sher,Sookhee Ha,Shu-Wei Yang,Mihir Mandal,Christine Yang,Lianzhu Liang,Zheng Tan,Paul Tawa,Yan Hou,Reshma Kuvelkar,Kristine Devito,Xiujuan Wen,Jing Xiao,Michelle Batchlett,Carl J. Balibar,Jenny Liu,Jianying Xiao,Nicholas Murgolo,Charles G. Garlisi,Payal R. Sheth,Amy M. Flattery,Jing Su,Christopher M. Tan,Terry Roemer +31 more
TL;DR: Tarocins and other inhibitors of wall teichoic acid biosynthesis may provide a rational strategy to develop Gram-positive bactericidal β-lactam combination agents active against methicillin-resistant staphylococci.
Journal ArticleDOI
A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts
Yaolin Wang,Philip Lipari,Xiaoying Wang,Judith Hailey,Lianzhu Liang,Robert A. Ramos,Ming Liu,Jonathan A. Pachter,W. Robert Bishop,Yan Wang +9 more
TL;DR: In vivo, SCH 717454 exhibits activity as a single agent and significantly inhibited growth of neuroblastoma, osteosarcoma, and rhabdomyosarca tumor xenografts and combined with cisplatin or cyclophosphamide enhanced both the degree and the duration of the in vivo antitumor activity compared with single-agent treatments.
Journal ArticleDOI
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core.
Tao Yu,Jayaram R. Tagat,Angela Kerekes,Doll Ronald J,Yonglian Zhang,Yushi Xiao,Sara Esposite,David B. Belanger,Patrick J. Curran,Amit K. Mandal,M. Arshad Siddiqui,Neng-Yang Shih,Andrea D. Basso,Ming Liu,Kimberly Gray,Seema Tevar,Jennifer Jones,Suining Lee,Lianzhu Liang,Samad Ponery,Elizabeth Smith,Alan Hruza,Johannes H. Voigt,Lata Ramanathan,Winifred W. Prosise,Mengwei Hu +25 more
TL;DR: Lead optimization guided by the binding mode led to the acyclic amino alcohol 12k (SCH 1473759), which is a picomolar inhibitor of Aurora kinases with improved cell potency and intrinsic aqueous solubility and demonstrated efficacy and target engagement in human tumor xenograft mouse models.